Evidence map›Paper›PMID 27783979›Full record

ArticleTranslational oncology2016

A Requirement for ZAK Kinase Activity in Canonical TGF-β Signaling.

Shyam Nyati, Areeb Chator, Katerina Schinske, Brandon S Gregg, Brian Dale Ross, Alnawaz Rehemtulla

Open access · goldAbstract read
In one paragraph

Article in Translational oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Heme-regulated inhibitor: an overlooked eIF2α kinase in cancer investigations.Medical oncology (Northwood, London, England) · 2022
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Shyam NyatiDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48105, USA; Center for Molecular Imaging, University of Michigan, Ann Arbor, MI 48105, USA. Electronic address: shyamnya@med.umich.edu.
Areeb ChatorDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48105, USA.
Katerina SchinskeDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48105, USA.
Brandon S GreggDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48105, USA.
Brian Dale RossDepartment of Radiology, University of Michigan, Ann Arbor, MI 48105, USA.
Alnawaz RehemtullaDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48105, USA; Center for Molecular Imaging, University of Michigan, Ann Arbor, MI 48105, USA; Department of Radiology, University of Michigan, Ann Arbor, MI 48105, USA. Electronic address: alnawaz@med.umich.edu.
University of Michigan–Ann Arbor · US

Funding

QUANTITATION OF HUMAN BRAIN TUMOR THERAPY RESPONSE BY MRP01CA085878 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ROSS, BRIAN D. · 2001 to 2017
$31.9M
Small Animal Imaging CoreP50CA093990 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ROSS, BRIAN D. · 2002 to 2012
$19.0M
Image Biomarker Development for TreatmentEfficacy of Prostate Cancer to the BoneR01CA136892 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ROSS, BRIAN D. · 2009 to 2012
$2.1M
NCI NIH HHS P01 CA085878NCI NIH HHS P50 CA093990NCI NIH HHS R01 CA136892
6 · The paper itself

Abstract

The sterile alpha motif and leucine zipper containing kinase ZAK (AZK, MLT, MLK7), is a MAPK-kinase kinase (MKKK). Like most MAPKKKs which are known to activate the c-Jun. amino-terminal kinase (JNK) pathway, ZAK has been shown to participate in the transduction of Transforming growth factor-β (TGF-β)-mediated non-canonical signaling. A role for ZAK in SMAD-dependent, canonical TGF-β signaling has not been previously appreciated. Using a combination of functional genomics and biochemical techniques, we demonstrate that ZAK regulates canonical TGFβRI/II signaling in lung and breast cancer cell lines and may serve as a key node in the regulation of TGFBR kinase activity. Remarkably, we demonstrate that siRNA mediated depletion of ZAK strongly inhibited TGF-β dependent SMAD2/3 activation and subsequent promoter activation (SMAD binding element driven luciferase expression; SBE4-Luc). A ZAK specific inhibitor (DHP-2), dose-dependently activated the bioluminescent TGFBR-kinase activity reporter (BTR), blocked TGF-β induced SMAD2/3 phosphorylation and SBE4-Luc activation and cancer cell-invasion. In aggregate, these findings identify a novel role for the ZAK kinase in canonical TGF-β signaling and an invasive cancer cell phenotype thus providing a novel target for TGF-β inhibition.

Identifiers

PMID27783979
PMCPMC5080675
OpenAlexW2538969819

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.